Clinical Trials Browser

Carcinoma, Neuroendocrine × sintilimab × NET × Clear all

NCT05113355 2021-11-24

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Phase 2 Unknown

Carcinoma, Neuroendocrine, Neuroendocrine Tumors